Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Gene Therapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.cgt.7701093PMID 17853920
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A demand for next-generation oncolytic adenoviruses.

  2006cited by this paper
• Enhanced Gene Transfer and Oncolysis of Head and Neck Cancer and Melanoma Cells by Fiber Chimeric Oncolytic Adenoviruses

  2006cited by this paper
• CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer

  2006cited by this paper
• Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus.

  2006cited by this paper
• Tumor-specific intravenous gene delivery using oncolytic adenoviruses

  2005cited by this paper
• Potent Antitumor Activity of Oncolytic Adenovirus Expressing mda-7/IL-24 for Colorectal Cancer

  2005cited by this paper
• Development of transcriptionally regulated oncolytic adenoviruses

  2005cited by this paper
• Recent progress in the battle between oncolytic viruses and tumours

  2005cited by this paper
• Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression.

  2005cited by this paper
• Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus.

  2005cited by this paper
• Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus

  2005cited by this paper
• Linked Tumor-Selective Virus Replication and Transgene Expression from E3-Containing Oncolytic Adenoviruses

  2005cited by this paper
• A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases.

  2004cited by this paper
• An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.

  2003cited by this paper
• Cancer Specific Viruses and the Development of ONYX-015

  2003cited by this paper
• E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

  2003cited by this paper
• In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF.

  2003cited by this paper
• Multigene expression from a replicating adenovirus using native viral promoters.

  2003cited by this paper
• The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses.

  2002cited by this paper
• Replication-selective viruses for cancer therapy

  2002cited by this paper
• A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene.

  2002cited by this paper
• Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents.

  2002cited by this paper
• Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes

  2002cited by this paper
• Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region

  2001cited by this paper
• Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region

  2001cited by this paper
• Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region

  2001cited by this paper
• Replicative adenoviruses for cancer therapy

  2000cited by this paper
• Generation of an Adenovirus Vector Lacking E1, E2a, E3, and All of E4 except Open Reading Frame 3

  1999cited by this paper
• The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.

  1999cited by this paper
• A simplified system for generating recombinant adenoviruses.

  1998cited by this paper
• A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy

  1998cited by this paper
• Splicing by overlap extension by PCR using asymmetric amplification: an improved technique for the generation of hybrid proteins of immunological interest.

  1997cited by this paper
• Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli

  1996cited by this paper
• Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy

  1996cited by this paper
• E3 transcription unit of adenovirus.

  1995cited by this paper
• Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

  1994cited by this paper
• Packaging capacity and stability of human adenovirus type 5 vectors

  1993cited by this paper
• At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells.

  1987cited by this paper
• Adenovirus promoters and E1A transactivation.

  1986cited by this paper
• Generation of adenovirus by transfection of plasmids.

  1983cited by this paper
• Transcripts from the adenovirus-2 major late promoter yield a single early family of 3' coterminal mRNAs and five late families.

  1980cited by this paper
• Infection of mouse liver by human adenovirus type 5.

  1978cited by this paper

• A novel GM-CSF-encoding oncolytic adenovirus induces profound autophagy and promotes viral replication to enhance anti-tumor efficacy

  2025cites this paper
• Comparison of the L3-23K and L5-Fiber Regions for Arming the Oncolytic Adenovirus Ad5-Delta-24-RGD with Reporter and Therapeutic Transgenes

  2025influential citation
• Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications

  2024cites this paper
• Engineered Human Adenoviruses of Species B and C Report Early, Intermediate Early, and Late Viral Gene Expression

  2023cites this paper
• Generation and Characterization of a Replication-Competent Human Adenovirus Type 55 Encoding EGFP

  2023cites this paper
• Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses

  2022cites this paper
• Concepts in Oncolytic Adenovirus Therapy

  2021cites this paper
• Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus

  2021cites this paper
• Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral Fitness

  2020influential citation
• Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses

  2020cites this paper
• 1. Translational Cancer Research

  2014cites this paper
• IMPROVING EFFICACY OF ADENOVIRAL CANCER GENE THERAPY

  2012cites this paper
• Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.

  2012cites this paper
• Oncolytic adenovirus vectors for nitroreductase suicide gene therapy of prostate cancer

  2010cites this paper
• Assessment and development of adenovirus type 11 for cancer therapy

  2010cites this paper
• Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles

  2010cites this paper
• Title : A novel immune-competent murine tumor model for the evaluation of conditionally replication-competent ( oncolytic ) murine adenoviral vectors

  2009cites this paper
• Armed replicating adenoviruses for cancer virotherapy

  2009cites this paper
• Recent developments in liver pathology.

  2009cites this paper
• Novel Immunocompetent Murine Tumor Model for Evaluation of Conditionally Replication-Competent (Oncolytic) Murine Adenoviral Vectors

  2009influential citation
• Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.

  2008cites this paper